Predictive analytics on multidimensional patient data will enable personalized precision medicine in the management of cardiometabolic disease to prevent catastrophic patient outcomes.
Deliver clinically actionable solutions in clinical decision support and patient management that healthcare providers and ecosystem stakeholders will use to change patient trajectories and improve outcomes
Dr Andrew Wu was previously Chief Operating Officer of Clearbridge Biomedics (now known as Biolidics) where he developed innovative cancer diagnostics technology in the field of liquid biopsy. He was also Chief Product Officer of Clearbridge Health. Both companies are now listed on SGX Catalist. Prior to Clearbridge, Andrew was Technical Director for CordLife, managing the laboratory operations and clinical affairs for the group.
Andrew holds a Bachelors and PhD in Biochemical Engineering from University College London.
Arsen Batagov was a former researcher in Russia, where he launched the Gene Diagnostics facility in the Russian Research Institute of Cardiology in 2003. In 2009, Arsen moved to Singapore and joined A*STAR, to focus on a broad range of bioinformatics and systems biology of cancers. He then served as the Bioinformatics Director in Vishuo Biomedical Ltd, Singapore before he co-founded Mesh Bio.
Arsen obtained his BSc and MSc in Genetics from St Petersburg Medical University, and pursued a PhD in Biochemical Engineering at University College London.
Dr Melvin Heng is the Co-Founder of Mesh Bio and currently the Chief Executive Officer at Gleneagles Hospital Singapore, part of the IHH Healthcare group. He was previously Director and Chief Information Officer of the Onecare Medical, a group of primary care clinics across Singapore. He is passionate about using digital technologies for healthcare delivery.
Melvin obtained his MBBS from St George’s Hospital in London, UK and a MBA in International Health from Frankfurt School of Finance & Management.
